NO985956L - Mixture for improved uptake of polar drugs from mucosal surfaces - Google Patents

Mixture for improved uptake of polar drugs from mucosal surfaces

Info

Publication number
NO985956L
NO985956L NO985956A NO985956A NO985956L NO 985956 L NO985956 L NO 985956L NO 985956 A NO985956 A NO 985956A NO 985956 A NO985956 A NO 985956A NO 985956 L NO985956 L NO 985956L
Authority
NO
Norway
Prior art keywords
mixture
mucosal surfaces
improved uptake
polar drugs
metabolizable
Prior art date
Application number
NO985956A
Other languages
Norwegian (no)
Other versions
NO985956D0 (en
Inventor
Lisbeth Illum
Peter James Watts
Original Assignee
Danbiosyst Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danbiosyst Uk Ltd filed Critical Danbiosyst Uk Ltd
Publication of NO985956L publication Critical patent/NO985956L/en
Publication of NO985956D0 publication Critical patent/NO985956D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Blanding for administrasjon til en mukosal overflate hos et pattedyr, omfattende en ikke-metaboliserbar gallesalt analog og en terapeutisk forbindelse. Den ikke-metaboli- serbare gallesalt-analogen er fortrinnsvis en forbindelse av cholin og ei aminosyre som ikke forekommer naturlig, spesielt cholylsarkosin. Den terapeutiske forbindelsen er fortrinnsvis et polart molekyl.A composition for administration to a mucosal surface of a mammal comprising a non-metabolizable bile salt analogue and a therapeutic compound. The non-metabolizable bile salt analogue is preferably a compound of choline and an amino acid that does not occur naturally, especially cholylsarcosine. The therapeutic compound is preferably a polar molecule.

NO985956A 1996-07-06 1998-12-18 Mixture for improved uptake of polar drugs from mucosal surfaces NO985956D0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9614235.1A GB9614235D0 (en) 1996-07-06 1996-07-06 Composition for enhanced uptake of polar drugs from mucosal surfaces
PCT/GB1997/001852 WO1998001159A2 (en) 1996-07-06 1997-07-07 Composition for enhanced uptake of polar drugs from mucosal surfaces

Publications (2)

Publication Number Publication Date
NO985956L true NO985956L (en) 1998-12-18
NO985956D0 NO985956D0 (en) 1998-12-18

Family

ID=10796483

Family Applications (1)

Application Number Title Priority Date Filing Date
NO985956A NO985956D0 (en) 1996-07-06 1998-12-18 Mixture for improved uptake of polar drugs from mucosal surfaces

Country Status (8)

Country Link
EP (1) EP0993305A2 (en)
JP (1) JP2000515503A (en)
KR (1) KR20000023583A (en)
AU (1) AU722724B2 (en)
CA (1) CA2257563A1 (en)
GB (2) GB9614235D0 (en)
NO (1) NO985956D0 (en)
WO (1) WO1998001159A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572874B1 (en) * 1998-05-15 2003-06-03 Umd, Inc. Vaginal delivery of bisphosphonates
JP2002537321A (en) * 1999-02-22 2002-11-05 エラン コーポレイション ピーエルスィー Solid oral dosage form containing enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
GB2355009A (en) 1999-07-30 2001-04-11 Univ Glasgow Peptides conjugated to bile acids/salts
US7053076B2 (en) 2001-08-29 2006-05-30 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
AU2003302888A1 (en) * 2002-12-11 2004-06-30 Chong Kun Dang Pharmaceutical Corp. Oral formulations for poorly absorptive hydrophilic drugs
DE102004027924A1 (en) * 2004-06-09 2005-12-29 Röhm GmbH & Co. KG Pharmaceutical form containing the active ingredient cholylsarcosine
US7704977B2 (en) 2006-04-07 2010-04-27 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
JP2011519928A (en) 2008-05-07 2011-07-14 メリオン・リサーチ・Ｉｉｉ・リミテッド Peptide composition and method for preparing the same
AU2010260211B2 (en) 2008-12-22 2016-04-21 Acerus Pharmaceuticals USA, LLC Safe desmopressin administration
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
AU2012204213A1 (en) 2011-01-07 2013-06-13 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
EP3250191B1 (en) 2015-01-29 2024-01-17 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating
CN108201531A (en) * 2016-12-19 2018-06-26 湖南尔康湘药制药有限公司 Segmented intestine targeted starch capsule of highly dissoluble sulbenicillin sodium and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994439A (en) * 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
DE4222647A1 (en) * 1991-07-15 1993-01-21 Sandoz Ag PEPTIDE PREPARATIONS
DK0708657T3 (en) * 1993-06-29 2001-10-15 Ferring Bv Compositions for nasal administration of desmopression
JPH11292787A (en) * 1995-08-15 1999-10-26 Asahi Chem Ind Co Ltd Transucosal preparation containing physiologically active peptide

Also Published As

Publication number Publication date
JP2000515503A (en) 2000-11-21
GB2330533B (en) 2000-10-25
GB2330533A (en) 1999-04-28
KR20000023583A (en) 2000-04-25
CA2257563A1 (en) 1998-01-15
AU3453997A (en) 1998-02-02
EP0993305A2 (en) 2000-04-19
GB9614235D0 (en) 1996-09-04
NO985956D0 (en) 1998-12-18
WO1998001159A2 (en) 1998-01-15
GB9900050D0 (en) 1999-02-24
WO1998001159A3 (en) 1998-03-26
AU722724B2 (en) 2000-08-10

Similar Documents

Publication Publication Date Title
NO985956L (en) Mixture for improved uptake of polar drugs from mucosal surfaces
PT951474E (en) NEW DERIVATIVES OF CICLOSPORIN ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
PT1115417E (en) USING DAPTOMYCIN
EA199900937A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING VORIKONAZOL
NO971889D0 (en) Compounds and compositions for delivery of active agents
BR9810312A (en) Pharmaceutical composition that has marked antitumor activity and / or reduced side effects containing an antitumor agent and a derivative of hydroxy acid
ID21956A (en) ACID N- (ARIL AND OR HETEROARILASETHL) AMINO ESTER, COMPOSITION OF THE PHARMACY CONTAINING IT, AND THE METHODS TO SPRIT THE BETHA-AMILOID PEPTIDES AND OR SYNTHESIAN COMPOSITION CONTAINING IT, AND THE METHODS TO SPRIT THE BETHA-AMILOID PEPTIDES AND OR SYNTHESIAN COMPOSITION THAT CONTAINS IT, AND THE METHODS TO SPRIT THE RELEASE OF BETHA-AMILOID PEPTIDES AND OR THE SYNTHESIA USING THE COMPOUND.
PT948527E (en) NEW CYCLOSPORAN DERIVATIVES HIS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
ATE260658T1 (en) PHARMACEUTICAL PREPARATIONS FOR REDUCING RESPIRATORY DEPRESSION
ATE424810T1 (en) A DELAYED-RELEASE TABLET CONTAINING A HYDROCOLLOID AND A CELLULOSE ETHER
DE69837324D1 (en) TREATMENT OF MULTIPLE SCLEROSIS BY USING COPOLYMER-1
HUP0302635A2 (en) Phospholipid derivatives of valproic acid and mixtures thereof
NO20015931L (en) Pharmaceutical formulations and methods comprising intranasal morphine
ES2033985T3 (en) A PROCEDURE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION.
LV12291A (en) Compound and pharmaceutical compositions for the treatment of related diseases by triptase activity
DK0796622T3 (en) Use of a gonadotropin-releasing hormone analogue or mimic thereof for the preparation of a pharmaceutical composition as an adjunct to the invasive treatment of carcinomas
CA2140361A1 (en) Composition and methods for decreasing muscle breakdown
BR9813319A (en) Compound, pharmaceutical composition for treating bacterial infections, and processes for treating bacterial infections and for preparing a compound
EA199800717A1 (en) METHOD FOR THE TREATMENT OF MAMMAL DISEASES AND THE CYVITTERION COMPOSITION
HK1024164A1 (en) Use of composition and a cosmetic method for reducing or preventing stinging
CO5060499A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROESOPHAGIC REFLECTION DISEASE
AR002191A1 (en) ORAL PHARMACEUTICAL COMPOSITION OF PIPERIDINOALCANOL COMPOUNDS IN THE FORM OF SOLUTION, PROCEDURE FOR ITS PREPARATION
BR9911756A (en) Compound, use of a growth hormone secretagogue or a pharmaceutically acceptable salt thereof, pharmaceutical composition, method to stimulate the release of growth hormone by a mammal's pituitary, and use of a compound
NO952987L (en) Wound healing mixture
WO1999052936A3 (en) Arginine peptide analogs useful as fibroblast growth factor antagonists

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application